RedChip Companies, Inc.

06/16/2026

Top scientists and Pfizer’s former CMO are backing Calidi Biotherapeutics (New York Stock Exchange American: CLDI).

Why? Because its systemic genetic delivery platform could redefine how we treat cancer.

🎥 Watch our 30-sec investor overview.
🔗 https://redchip.news/4nLmPXR

Northwestern University City of Hope The Lancet PharmaVoice Genetic Engineering & Biotechnology News

Why are top biotech leaders — including Pfizer’s former Chief Medical Officer — joining forces with a small-cap company like Calidi Biotherapeutics (NYSE Ame...

06/15/2026

⏳ Starting in 30 Minutes — Last Chance to Register: New Horizon Aircraft (Nasdaq: HOVR) RedChip Investor Webinar at 4:15 PM ET

This is your final call. The New Horizon Aircraft RedChip Investor Webinar kicks off in 30 minutes, and there is still time to register and join live.

⏱️ Last chance to hear directly on:
- The Cavorite X7's patented fan-in-wing design: vertical takeoff and landing with the speed, range, and efficiency of a fixed-wing aircraft
- AFWERX selection: chosen as 1 of 5 from ~250 applicants in the U.S. Air Force High-Speed VTOL program, validating both technical credibility and defense market applicability
- A ~$1 trillion advanced air mobility market opportunity, with ~70,000 legacy helicopters globally representing a significant long-term replacement target
- Full-scale aircraft under construction, flight testing targeted for 2027, and a defined Transport Canada certification pathway with potential FAA reciprocity

Register now and join the live session — HOVR management takes the floor in 30 minutes.

🔗 Register here: https://redchip.news/3PfXE2V

RedChip's comprehensive IR platform is the ideal solution for small- and mid-cap companies who want to increase their retail and institutional shareholder base.

06/15/2026

⏳ STARTING IN 30 MINUTES: New Horizon Aircraft (Nasdaq: HOVR) Live Investor Webinar — 4:15 PM ET | Last Chance to Register

This is your final call. The RedChip investor webinar with New Horizon Aircraft begins in 30 minutes — at 4:15 PM ET today. The combination of hybrid-electric propulsion, a patented fan-in-wing design, 30+ patents, U.S. Air Force validation, and a clean balance sheet with $20.0M in cash and zero long-term debt is an investment profile that is difficult to find at this stage in any aerospace company — let alone one in a sector with a ~$1 trillion projected market.

⚡ Last look at the investment case:
- ~250 mph target speed and ~500-mile range — approximately 2x helicopters
- ~$0.97 per seat mile operating cost vs. ~$4–$6 for comparable helicopters
- 1 of 5 winners selected from ~250 applicants in the U.S. Air Force AFWERX High-Speed VTOL program
- $20.0M cash, zero long-term debt, and 34.8% insider ownership

30 minutes. Register now — this is your last chance.

🔗 Register here: https://redchip.news/3PfXE2V

Hangar X Studios Aviation International News Breaking Defense Royal Aeronautical Society Top Aces

RedChip's comprehensive IR platform is the ideal solution for small- and mid-cap companies who want to increase their retail and institutional shareholder base.

06/15/2026

⚡ Bimergen Energy (NYSE American: BESS) — Building the Battery Farms the US Grid Needs
Grid-scale battery storage is one of the fastest-growing segments of the US energy economy — and Bimergen Energy is already sitting on a 23-project, ~2.0 GW development pipeline to meet that demand.

Co-CEO Bob Brillin joined RedChip to walk through how the business works, covering:
- A 23-project pipeline acquired in April 2024, giving Bimergen roughly 4 years of built-in deal flow
- Two revenue streams: up to $8M per project upon JV formation, plus ~$20M in annual energy arbitrage per 100 MW site
- How federal investment tax credits of up to 50% of project capex can be monetized at commercial operation

Here's how Bob described the hidden value in the pipeline:
"We're so new, nobody really knows about us... if you take that $8 million we're going to get for each one of those as they go into a joint venture, you're talking about $150 million worth of value there that's not showing up in our shareholder value at this point."

Is this a story the market hasn't fully discovered yet? Watch the full interview and decide for yourself.

▶️ Watch the full interview: https://redchip.news/4vHHpei

S&P Global Energy Commodity Insights Renewables Now

Co-CEO Bob Brilon joins RedChip to discuss Bimergen Energy's (NYSE ...

06/15/2026

⚛️ ASP Isotopes (Nasdaq: ASPI) CEO Paul Mann: Commercial isotope ramp, Silicon 28 validation, and the 2026 inflection setup

Watch our exclusive interview with ASP Isotopes' CEO Paul Mann covering what investors should be watching as ASPI moves from buildout to commercialization.

💡 ASPI is leveraged to several high priority markets spanning nuclear medicine, semiconductors, helium, and nuclear fuels, with the near-term opportunity centered on turning validated products into sustained commercial deliveries that can support cash generation and scale.

🔗 Watch our full interview: https://redchip.news/4qDuze8

World Nuclear News S&P Global Energy Nuclear Energy Institute

06/15/2026

🎬 Alliance Entertainment (Nasdaq: AENT): CEO Jeff Walker Featured in Media Play News as Physical Media's Collector Economy Takes Center Stage

CEO Jeff Walker was quoted in a major Media Play News feature examining how e-commerce, collector culture, and creative merchandising are reshaping the home entertainment retail business.

On the rise of online retail: "Online retail has become a primary discovery and purchase channel because it aligns naturally with how fans engage, explore and build their collections today."

On the enduring value of physical stores: "Physical retail remains essential. In-store delivers something digital cannot replicate — the immediacy and delight of discovery within a curated, trusted environment."

Together, the quotes frame Alliance's omnichannel advantage precisely. The company operates Movies Unlimited, DeepDiscount.com, and Critics' Choice Video as direct-to-consumer e-commerce platforms while simultaneously fulfilling orders for 35,000+ retail storefronts globally — capturing demand wherever collectors shop, and holding 9% U.S. disc market share in the process.

🔗 Read the full article: https://redchip.news/4vRfl8p

Media Play News Supply Chain Management Review The Logistics Review

Movies, Music, Vinyl and More at the Guaranteed Lowest Price. Free Shipping on Orders over $25! DVDs, CDs, Blu-ray, LP, Boxed Sets, New Releases, Hard To Find, Imports

06/15/2026

📣 ASP Isotopes (Nasdaq: ASPI) | Investor Webinar | 2 Days Away — June 17 at 11:00 AM ET — If You Haven't Registered Yet, Now Is the Time

In two days, ASP Isotopes will give investors a direct line to leadership at one of the more consequential inflection points in the company's history. If you're tracking the critical materials space — semiconductors, quantum computing, advanced nuclear, radiopharmaceuticals — this is a webinar you shouldn't be reading about after the fact.

⚛️ What's on the table on June 17:
- Progress update on Silicon-28 and Ytterbium-176 commercial contract fulfillment targeted for 1H 2026
- Construction plans for new facilities in Iceland, the U.S., and the UK in 2026
- Pipeline expansion into Nickel-64, Gadolinium-160, Xe-129, and Zn-68, addressing acute Western shortages
- Renergen integration update and the de-risked scale-up pathway supported by up to $750M in committed financing

Register before June 17 and come prepared with your questions for ASPI's leadership team.

🔗 Register here: https://redchip.news/43xNii4

S&P Global Energy World Nuclear News TechCrunch

06/15/2026

📽️ Greenwich LifeSciences: A Quick Look at a Promising Phase III Breast Cancer Therapy

Greenwich (Nasdaq: GLSI) is making major strides in the fight against breast cancer. Its lead immunotherapy candidate, GLSI-100, is now in a global Phase III trial (FLAMINGO-01), spanning 150 sites across the U.S. and Europe, targeting up to 750 HER2+ breast cancer patients.

💡 Why This Matters to Investors:
• Breakthrough Potential: Aims to reduce recurrence rates by over 80%, outperforming current HER2 therapies.
• Robust Safety Profile: Supported by ongoing Data Safety Monitoring Board reviews with no changes required.
• Global Validation: Backed by elite research groups across the U.S. and EU.

🔗 https://bit.ly/3VgiJJF

Greenwich LifeSciences (Nasdaq: GLSI) is a clinical-stage biopharma...

06/15/2026

🤖 SharonAI Holdings Inc. (Nasdaq: SHAZ): 600PB VAST AI OS Deployment Cements Sharon AI as Asia-Pacific's Sovereign AI Infrastructure Leader

Sharon AI just announced a major expansion of its strategic partnership with VAST Data, committing to deploy 600 petabytes of the VAST AI Operating System across its cloud infrastructure, making it the foundational data layer for Sharon AI's sovereign AI platform serving government, enterprise, research, and AI-native customers across Australia and Asia-Pacific.

📊 Why investors are watching:
- 600PB VAST AI OS deployment — one of the largest sovereign AI data foundations in the Asia-Pacific region, supporting next-generation training, inference, and agentic AI workloads
- ~100,000 GPU-equivalent data backbone — scalable architecture built on VAST's DASE technology, delivering a single global namespace with no data movement bottlenecks
- 54MW GPU capacity targeted in 2026 — customer-led deployment model backed by strategic partners NVIDIA, Cisco, World Wide Technology, and NEXTDC
- Certified NVIDIA Cloud Partner — one of only three in Australia, with Australia's first Cisco Secure AI Factory already live at NEXTDC's S3 Sydney facility featuring 1,024 NVIDIA Blackwell Ultra GPUs

🔗 Read the full press release: https://redchip.news/4emg4ay

TechCrunch

06/15/2026

CEO James Foster breaks down Virax Biolabs' (Nasdaq: VRAX) lead program, ViraxImmune™ — a next-generation blood-based immune function test targeting post-acute infection syndromes (PAIS), including Long COVID and ME/CFS.

An estimated 21 million people in the U.S. are affected by PAIS conditions, with 2.5 million new cases annually — yet there is currently no widely adopted objective diagnostic test. ViraxImmune™ is designed to change that by delivering objective immune dysfunction profiling where routine blood tests fall short.

👉 For the full interview: https://redchip.news/43ki5yZ

FierceBiotech Genetic Engineering & Biotechnology News PharmaVoice